Valtoco

Athetosis, Lockjaw, Syndrome + 11 more

Treatment

20 Active Studies for Valtoco

What is Valtoco

Diazepam

The Generic name of this drug

Treatment Summary

Diazepam is a type of anti-anxiety medication that helps to reduce seizures, anxiety, and insomnia. It works by increasing the activity of a brain chemical called gamma-aminobutyric acid. It has been used for many years to treat a variety of conditions and recently, an auto-injectable form was approved by the FDA. This form is used to quickly and effectively treat uncontrolled seizures and is an important tool for people with epilepsy.

Valium

is the brand name

image of different drug pills on a surface

Valtoco Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Valium

Diazepam

1963

289

Effectiveness

How Valtoco Affects Patients

Diazepam is a type of medicine that helps to reduce anxiety, make people sleepy, relax muscles, and stop seizures. It is believed that these effects come from its ability to help increase the activity of the chemical called GABA in the brain, which helps to slow down the nervous system.

How Valtoco works in the body

Diazepam is a medication that helps relax muscles, reduce seizures, and make you drowsy. It works by attaching to receptors in the brain and spinal cord. This boosts the effects of a chemical in the body called GABA, which helps with sleep, memory, anxiety, and controlling overactivity in the nervous system.

When to interrupt dosage

The prescribed dosage of Valtoco is contingent upon the diagnosed condition, including Muscle Tissue, Seizures and Anger Management Therapy. The amount of dosage depends upon the method of administration outlined in the table beneath.

Condition

Dosage

Administration

Drug Resistant Epilepsy

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Seizures

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Anger Management Therapy

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Muscle Tissue

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Athetosis

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Lockjaw

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Syndrome

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Motor Neuron Disease, Upper

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Sedation therapy

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Sedation

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Generalized Anxiety Disorder

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Anxiety Disorders

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Stiff-Person Syndrome

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Status Epilepticus

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Warnings

Valtoco has six contraindications and should not be combined when suffering from any of the conditions indicated in the table below.

Valtoco Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Obstructive Sleep Apnea (OSA)

Do Not Combine

Glaucoma

Do Not Combine

Myasthenia Gravis

Do Not Combine

Liver Failure

Do Not Combine

Respiratory Insufficiency

Do Not Combine

There are 20 known major drug interactions with Valtoco.

Common Valtoco Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Diazepam.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Diazepam.

Azelastine

Major

Diazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diazepam.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Diazepam.

Valtoco Toxicity & Overdose Risk

Overdosing on diazepam can lead to an intensification of the drug's effects, such as drowsiness, difficulty speaking, and weakened muscles. More severe symptoms include coma, loss of reflexes, slowed breathing and heart rate, and lack of oxygen. Taking diazepam with other drugs or alcohol can be fatal and should be avoided. Pregnant women should avoid taking diazepam altogether, and it is not recommended for breastfeeding mothers or children under 6 months of age. Elderly patients should take the smallest dose possible as they are more likely to have side effects. Patients with cirrhosis, hepatic encephal

image of a doctor in a lab doing drug, clinical research

Valtoco Novel Uses: Which Conditions Have a Clinical Trial Featuring Valtoco?

409 active clinical trials are currently investigating the potential of Valtoco to alleviate Anxiety Disorders, Generalized Anxiety Disorder and Stiff Man Syndrome.

Condition

Clinical Trials

Trial Phases

Anxiety Disorders

56 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Generalized Anxiety Disorder

183 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Lockjaw

0 Actively Recruiting

Stiff-Person Syndrome

4 Actively Recruiting

Phase 2, Phase 1

Sedation

2 Actively Recruiting

Early Phase 1, Not Applicable

Motor Neuron Disease, Upper

0 Actively Recruiting

Athetosis

1 Actively Recruiting

Phase 3

Drug Resistant Epilepsy

1 Actively Recruiting

Not Applicable

Sedation therapy

0 Actively Recruiting

Status Epilepticus

0 Actively Recruiting

Seizures

0 Actively Recruiting

Muscle Tissue

0 Actively Recruiting

Anger Management Therapy

0 Actively Recruiting

Patient Q&A Section about valtoco

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Valtoco a narcotic?

"Valtoco nasal spray is a prescription medicine used to treat seizure clusters in adults and children who are at least 6 years old. Valtoco can be abused and can lead to dependence, so it is classified as a federal controlled substance (C-IV)."

Answered by AI

Can Valtoco be used for anxiety?

"Diazepam - FDA prescribing information, side effects and uses

Diazepam is used to treat anxiety disorders, alcohol withdrawal symptoms, or muscle spasms. It can also be used to relieve seizures."

Answered by AI

Is Valtoco a diazepam?

"Diazepam, which is the active ingredient in VALTOCO, has been used by medical professionals to treat epilepsy for over 50 years. For the last 20 years, patients and their carers have also used diazepam to rescue themselves from episodes of frequent seizure activity outside of a medical setting."

Answered by AI

What is Valtoco used for?

"The FDA has approved Valtoco, a new seizure medicine designed to treat periods of frequent seizures or cluster seizures that are distinct from the person's usual seizure pattern."

Answered by AI

Clinical Trials for Valtoco

Have you considered Valtoco clinical trials?

We made a collection of clinical trials featuring Valtoco, we think they might fit your search criteria.
Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Have you considered Valtoco clinical trials?

We made a collection of clinical trials featuring Valtoco, we think they might fit your search criteria.
Go to Trials
Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Image of Birmingham VA in Birmingham, United States.

Transcranial Alternating Current Stimulation for Anxiety

19 - 70
All Sexes
Birmingham, AL

Transcranial alternating current stimulation (tACS) in a wearable brain stimulation device that delivers a low intensity, pulsed, alternating current via scalp electrodes. Prior sham-controlled clinical trials have shown the therapeutic effects and safety of tACS for the treatment of anxiety and depression. In addition, tACS is rapid acting and well tolerated. After the device is issued to the patient during an in-office orientation and training session, the tACS device can be safely used by the patient at the convenience of their own home. Up to 40 Veterans under that age of 70 who have clinically significant anxiety will be enrolled in an 8-week open-label trial of Model FW-200 tACS to evaluate feasibility, acceptability, adherence and impact on anxiety, depression, post-traumatic stress disorder (PTSD), sleep and neurocognitive measures. Participants may have a concurrent diagnosis of major depressive disorder (MDD) and/or PTSD.

Recruiting
Has No Placebo

Birmingham VA

Lori Davis, MD

Fisher Wallace Laboratories

Have you considered Valtoco clinical trials?

We made a collection of clinical trials featuring Valtoco, we think they might fit your search criteria.
Go to Trials